Published in J Natl Cancer Inst on November 11, 2008
Clinical utility of vitamin d testing: an evidence-based analysis. Ont Health Technol Assess Ser (2010) 0.83
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst (2008) 3.60
Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med (2007) 2.95
Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med (2007) 2.83
Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet (1985) 2.62
Intake of dairy products, calcium, and vitamin d and risk of breast cancer. J Natl Cancer Inst (2002) 2.16
Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer (2005) 1.83
Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5. J Natl Cancer Inst (1997) 1.67
Relation of calcium, vitamin D, and dairy food intake to incidence of colon cancer among older women. The Iowa Women's Health Study. Am J Epidemiol (1993) 1.57
Dairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev (2005) 1.44
Dietary intake of selected micronutrients and breast-cancer risk. Int J Cancer (2001) 1.35
Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa Women's Health Study. Cancer Causes Control (2007) 1.33
Plasma vitamin D and risk of colorectal cancer: the Japan Public Health Center-Based Prospective Study. Br J Cancer (2007) 1.22
Calcium, vitamin D, dairy foods, and the occurrence of colorectal adenomas among men and women in two prospective studies. Am J Epidemiol (1994) 1.19
Vitamin D, calcium and prevention of breast cancer: a review. J Am Coll Nutr (1999) 1.16
Intake of food groups and associated micronutrients in relation to risk of early-stage breast cancer. Int J Cancer (1999) 1.13
Dietary vitamin D and calcium intake and premenopausal breast cancer risk in a German case-control study. Nutr Cancer (2007) 1.08
Intake of selected foods and nutrients and breast cancer risk: an age- and menopause-specific analysis. Nutr Cancer (1997) 0.88
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst (2003) 2.49
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2013) 2.21
The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res (2004) 2.04
Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res (2009) 1.48
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics (2011) 1.32
American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol (2008) 1.29
Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2012) 1.17
Tamoxifen inhibition of estrogen receptor-alpha-negative mouse mammary tumorigenesis. Cancer Res (2005) 1.09
Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat (2009) 1.04
The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clin Cancer Res (2006) 1.03
Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila) (2012) 1.01
Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. Neoplasia (2013) 0.88
Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. Breast Cancer Res Treat (2013) 0.86
Aromatase inhibitors for the treatment and prevention of breast cancer. Clin Breast Cancer (2005) 0.79
Should tamoxifen be used in breast cancer prevention? Drug Saf (2004) 0.78
Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer. Breast Cancer Res Treat (2014) 0.78
Defining the role of raloxifene for the prevention of breast cancer. J Natl Cancer Inst (2004) 0.77
Imaging in thoracic oncology: case studies from Multidisciplinary Thoracic Tumor Board (part 1 of 2 part series). Cancer Imaging (2013) 0.75
Imaging in thoracic oncology: case studies from Multidisciplinary Thoracic Tumor Board: (part 2 of 2 part series). Cancer Imaging (2013) 0.75
Is low-dose tamoxifen useful for the treatment and prevention of breast cancer? J Natl Cancer Inst (2003) 0.75
Prevention of breast cancer--present reality and future promise. J Mammary Gland Biol Neoplasia (2003) 0.75
Radiogenomics and radiotherapy response modeling. Phys Med Biol (2017) 0.75